8 known cases. View patent page →
Jazz Pharmaceuticals, Inc. sued Amneal Pharmaceuticals LLC in D.N.J., asserting U.S. Patent 9,050,302 among others. The case was part of the consolidated Xyrem ANDA litigation before Judge Esther Salas and is closed.
Case listed in the Google Patents litigation record for U.S. Patent 9,050,302 as part of the Jazz Xyrem ANDA wave; parties not independently confirmed.
Jazz Pharmaceuticals, Inc. et al. sued Ascent Pharmaceuticals, Inc. in E.D.N.Y. involving U.S. Patent 9,050,302. Jazz voluntarily dismissed the action on Aug. 30, 2017.
Ranbaxy Inc. filed an IPR against Jazz Pharmaceuticals Ireland Limited concerning U.S. Patent 9,050,302. The proceeding was terminated by settlement, with termination judgment entered May 23, 2016.
Jazz sued Lupin over Lupin's ANDA No. 215911 for generic Xywav; the complaint expressly lists the '426 patent among ten patents-in-suit. Lupin answered and counterclaimed; the case was consolidated with later Lupin suits and the Teva action, with no final merits judgment on the '426 patent found.
Jazz sued Teva over Teva's ANDA for generic Xywav; the complaint lists the '426 patent among the patents-in-suit. Teva filed invalidity contentions and counterclaims; the case was consolidated with the Lupin actions on Dec. 15, 2023, and remains ongoing with no final judgment on '426 found.
Jazz sued Alkem in a Xyrem-related ANDA action; the complaint asserted the '426 patent plus other patents. The case was voluntarily dismissed, with a Rule 41(a)(1)(A)(i) order signed Oct. 5, 2023, and the case terminated.
Jazz sued Tris Pharma over Tris's January 2026 Section 505(b)(2) NDA for generic Xyrem/Xywav; this docket lists the '426 patent among asserted patents and also lists '400, '181, '494, '446, '306, and '302. The matter appears active.